1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

BACKGROUND: RSVPreF3 OA was recently approved by the United States FDA for the prevention of RSV-related lower respiratory tract disease (RSV-LRTD) in adults ≥ 60 years of age (YOA). We present persistence of vaccine efficacy (VE) of a single RSVPreF3 OA dose, along with VE and safety of annual reva...

Descripción completa

Detalles Bibliográficos
Autores principales: Ison, Michael G, Papi, Alberto, Langley, Joanne M, Lee, Dong-Gun, Leroux-Roels, Isabel, Martinon-Torres, Federico, Schwarz, Tino F, Van Zyl-Smit, Richard N, Cuadripani, Susanna, Dezutter, Nancy, Gruselle, Olivier, Fissette, Laurence, David, Marie-Pierre, Olivier, Aurélie, Der Wielen, Marie Van, Descamps, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678697/
http://dx.doi.org/10.1093/ofid/ofad500.2467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678697/
http://dx.doi.org/10.1093/ofid/ofad500.2467

Ejemplares similares